Loading...

NuVasive

DB:NK8
Snowflake Description

Reasonable growth potential with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NK8
DB
$3B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. The last earnings update was 21 days ago. More info.


Add to Portfolio Compare Print
NK8 Share Price and Events
7 Day Returns
4.1%
DB:NK8
1.2%
DE Medical Equipment
-0%
DE Market
1 Year Returns
32.1%
DB:NK8
12.7%
DE Medical Equipment
-11.5%
DE Market
NK8 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
NuVasive (NK8) 4.1% 16.1% 15.9% 32.1% 15.2% 137.6%
DE Medical Equipment 1.2% 2% 4.4% 12.7% 102.6% 232.2%
DE Market -0% -3.3% 2.1% -11.5% 8.9% 8.1%
1 Year Return vs Industry and Market
  • NK8 outperformed the Medical Equipment industry which returned 12.7% over the past year.
  • NK8 outperformed the Market in Germany which returned -11.5% over the past year.
Price Volatility
NK8
Industry
5yr Volatility vs Market

Value

 Is NuVasive undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of NuVasive to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for NuVasive.

DB:NK8 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 18 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.4%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:NK8
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.9
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.895 (1 + (1- 21%) (21.09%))
1.03
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.03
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.03 * 5.96%)
6.37%

Discounted Cash Flow Calculation for DB:NK8 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for NuVasive is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:NK8 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.37%)
2019 102.89 Analyst x2 96.73
2020 132.89 Analyst x3 117.46
2021 134.50 Analyst x2 111.77
2022 135.72 Est @ 0.91% 106.04
2023 136.68 Est @ 0.71% 100.40
2024 137.45 Est @ 0.56% 94.92
2025 138.09 Est @ 0.46% 89.65
2026 138.63 Est @ 0.39% 84.62
2027 139.10 Est @ 0.34% 79.82
2028 139.53 Est @ 0.31% 75.28
Present value of next 10 years cash flows $956.69
DB:NK8 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $139.53 × (1 + 0.23%) ÷ (6.37% – 0.23%)
$2,278.68
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,278.68 ÷ (1 + 6.37%)10
$1,229.37
DB:NK8 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $956.69 + $1,229.37
$2,186.06
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,186.06 / 51.89
$42.13
DB:NK8 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:NK8 represents 0.89137x of NasdaqGS:NUVA
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.89137x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 42.13 x 0.89137
€37.56
Value per share (EUR) From above. €37.56
Current discount Discount to share price of €55.47
= -1 x (€55.47 - €37.56) / €37.56
-47.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of NuVasive is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for NuVasive's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are NuVasive's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:NK8 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $0.95
NasdaqGS:NUVA Share Price ** NasdaqGS (2019-05-22) in USD $62.23
Germany Medical Equipment Industry PE Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 35.61x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 20.26x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of NuVasive.

DB:NK8 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:NUVA Share Price ÷ EPS (both in USD)

= 62.23 ÷ 0.95

65.4x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NuVasive is overvalued based on earnings compared to the DE Medical Equipment industry average.
  • NuVasive is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does NuVasive's expected growth come at a high price?
Raw Data
DB:NK8 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 65.4x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 18 Analysts
38%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 3.1x
Germany Market PEG Ratio Median Figure of 271 Publicly-Listed Companies 1.49x

*Line of best fit is calculated by linear regression .

DB:NK8 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 65.4x ÷ 38%

1.72x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NuVasive is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on NuVasive's assets?
Raw Data
DB:NK8 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $16.20
NasdaqGS:NUVA Share Price * NasdaqGS (2019-05-22) in USD $62.23
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.17x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.78x
DB:NK8 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:NUVA Share Price ÷ Book Value per Share (both in USD)

= 62.23 ÷ 16.20

3.84x

* Primary Listing of NuVasive.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NuVasive is good value based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess NuVasive's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. NuVasive has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is NuVasive expected to perform in the next 1 to 3 years based on estimates from 18 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
38%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is NuVasive expected to grow at an attractive rate?
  • NuVasive's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • NuVasive's earnings growth is expected to exceed the Germany market average.
  • NuVasive's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:NK8 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:NK8 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 18 Analysts 38%
DB:NK8 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 18 Analysts 5%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 12.7%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:NK8 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 18 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:NK8 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 1,348 2
2021-12-31 1,274 268 113 12
2020-12-31 1,215 258 91 18
2019-12-31 1,155 196 51 18
DB:NK8 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 1,116 207 49
2018-12-31 1,102 219 12
2018-09-30 1,087 211 25
2018-06-30 1,063 189 43
2018-03-31 1,038 185 42
2017-12-31 1,027 177 82
2017-09-30 1,027 179 64
2017-06-30 1,019 123 35
2017-03-31 996 127 53
2016-12-31 962 158 37
2016-09-30 906 137 42
2016-06-30 867 154 51

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • NuVasive's earnings are expected to grow significantly at over 20% yearly.
  • NuVasive's revenue is expected to grow by 5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:NK8 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 18 Analyst Estimates (S&P Global) See Below

All data from NuVasive Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NK8 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31
2021-12-31 2.09 2.31 1.82 5.00
2020-12-31 1.70 1.98 1.54 7.00
2019-12-31 1.01 1.18 0.88 7.00
DB:NK8 Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 0.95
2018-12-31 0.24
2018-09-30 0.49
2018-06-30 0.84
2018-03-31 0.82
2017-12-31 1.60
2017-09-30 1.27
2017-06-30 0.69
2017-03-31 1.05
2016-12-31 0.74
2016-09-30 0.85
2016-06-30 1.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • NuVasive is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess NuVasive's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
NuVasive has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has NuVasive performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare NuVasive's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • NuVasive has delivered over 20% year on year earnings growth in the past 5 years.
  • NuVasive's 1-year earnings growth is less than its 5-year average (16.5% vs 22.6%)
  • NuVasive's earnings growth has exceeded the DE Medical Equipment industry average in the past year (16.5% vs 3.2%).
Earnings and Revenue History
NuVasive's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from NuVasive Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NK8 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 1,115.97 49.00 574.15 64.78
2018-12-31 1,101.71 12.48 575.84 61.70
2018-09-30 1,087.44 25.21 568.56 57.32
2018-06-30 1,063.19 42.81 553.00 54.79
2018-03-31 1,038.19 42.04 545.91 52.50
2017-12-31 1,026.69 81.60 539.51 50.43
2017-09-30 1,026.57 64.50 547.40 50.69
2017-06-30 1,019.17 34.90 553.63 50.49
2017-03-31 995.98 52.94 549.15 49.78
2016-12-31 962.13 37.19 533.60 48.00
2016-09-30 906.25 42.27 510.05 43.62
2016-06-30 867.13 51.31 488.72 40.30
2016-03-31 833.83 31.36 468.32 37.20
2015-12-31 811.11 66.29 457.28 35.83
2015-09-30 800.16 62.26 453.71 36.62
2015-06-30 789.54 47.47 456.90 36.50
2015-03-31 777.30 33.12 459.78 37.80
2014-12-31 762.42 -16.72 456.70 37.49
2014-09-30 748.91 -18.19 457.38 36.15
2014-06-30 728.14 -8.84 445.66 34.32
2014-03-31 703.17 -11.23 432.93 31.97
2013-12-31 685.17 7.90 420.06 32.21
2013-09-30 660.11 -0.85 403.23 33.05
2013-06-30 639.35 -6.01 388.50 33.38
2013-03-31 628.07 3.32 376.68 35.00
2012-12-31 620.26 3.14 372.42 35.30
2012-09-30 604.70 -4.15 367.52 34.19
2012-06-30 589.18 -74.05 365.70 36.70

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • NuVasive has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • NuVasive used its assets less efficiently than the DE Medical Equipment industry average last year based on Return on Assets.
  • NuVasive has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess NuVasive's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
NuVasive has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is NuVasive's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up NuVasive's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • NuVasive is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • NuVasive's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of NuVasive's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from NuVasive Company Filings, last reported 1 month ago.

DB:NK8 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 840.01 681.04 93.39
2018-12-31 834.53 602.53 117.84
2018-09-30 803.62 602.52 75.11
2018-06-30 781.16 629.58 70.08
2018-03-31 762.40 642.72 73.74
2017-12-31 799.42 582.92 72.80
2017-09-30 760.20 618.19 62.20
2017-06-30 723.61 656.83 130.93
2017-03-31 698.73 631.43 134.01
2016-12-31 700.52 626.11 153.64
2016-09-30 722.81 680.93 203.82
2016-06-30 707.86 674.94 317.16
2016-03-31 651.69 669.40 312.60
2015-12-31 718.84 372.92 357.76
2015-09-30 691.69 372.49 337.37
2015-06-30 675.36 368.50 278.69
2015-03-31 663.48 364.59 289.30
2014-12-31 648.36 360.75 362.72
2014-09-30 632.41 356.97 300.48
2014-06-30 628.31 353.27 247.31
2014-03-31 604.49 349.63 287.39
2013-12-31 604.88 346.06 246.27
2013-09-30 578.12 342.55 209.83
2013-06-30 557.18 339.11 172.66
2013-03-31 553.17 335.73 200.37
2012-12-31 547.58 407.14 261.70
2012-09-30 541.80 403.45 242.63
2012-06-30 533.01 400.25 241.81
  • NuVasive's level of debt (81.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (57.8% vs 81.1% today).
  • Debt is well covered by operating cash flow (30.4%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 3.1x coverage).
X
Financial health checks
We assess NuVasive's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. NuVasive has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is NuVasive's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from NuVasive dividends. Estimated to be 0% next year.
If you bought €2,000 of NuVasive shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate NuVasive's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate NuVasive's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:NK8 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 18 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:NK8 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31 0.00 3.00
2020-12-31 0.00 4.00
2019-12-31 0.00 4.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as NuVasive has not reported any payouts.
  • Unable to verify if NuVasive's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of NuVasive's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as NuVasive has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of NuVasive's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess NuVasive's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can NuVasive afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. NuVasive has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of NuVasive's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chris Barry
COMPENSATION $5,116,274
AGE 45
TENURE AS CEO 0.5 years
CEO Bio

Mr. J. Christopher Barry serves as CEO and Director of NuVasive, Inc. since November 5, 218. Mr. Barry served commercial and leadership roles at Covidien. He has extensive experience as an innovative global leader in the healthcare and medical device industry. Mr. Barry served as senior vice president and president of Surgical Innovations, the second-largest business unit at Medtronic with $5.5 billion in annual revenue. In this role, Mr. Barry leads and provides strategic direction to more than 14,000 employees working in 78 countries, including 10 manufacturing sites and multiple R&D centers around the globe.

CEO Compensation
  • Insufficient data for Chris to compare compensation growth.
  • Chris's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the NuVasive management team in years:

1.3
Average Tenure
43.5
Average Age
  • The average tenure for the NuVasive management team is less than 2 years, this suggests a new team.
Management Team

Chris Barry

TITLE
CEO & Director
COMPENSATION
$5M
AGE
45
TENURE
0.5 yrs

Matt Link

TITLE
President
COMPENSATION
$3M
AGE
43
TENURE
0.3 yrs

Rajesh Asarpota

TITLE
Executive VP & CFO
COMPENSATION
$2M
AGE
51
TENURE
1.7 yrs

Jereme Sylvain

TITLE
Chief Accounting Officer
AGE
38
TENURE
2.8 yrs

Johnson Lai

TITLE
Chief Information Officer
TENURE
3.8 yrs

Suzanne Hatcher

TITLE
Vice President of Internal & External Affairs

Nathaniel Sisitsky

TITLE
Senior VP
AGE
44
TENURE
1.3 yrs

Jim Garrett

TITLE
Chief Compliance Officer
TENURE
0.3 yrs

Lucas Vitale

TITLE
Chief Human Resources Officer
AGE
42
TENURE
0.3 yrs

Frank Middeke

TITLE
Managing Director of DACH
TENURE
5.4 yrs
Board of Directors Tenure

Average tenure and age of the NuVasive board of directors in years:

3
Average Tenure
56
Average Age
  • The tenure for the NuVasive board of directors is about average.
Board of Directors

Greg Lucier

TITLE
Chairman of the Board
COMPENSATION
$5M
AGE
54
TENURE
4.2 yrs

Chris Barry

TITLE
CEO & Director
COMPENSATION
$5M
AGE
45
TENURE
0.5 yrs

Leslie Norwalk

TITLE
Director
COMPENSATION
$234K
AGE
53
TENURE
5 yrs

Vickie Capps

TITLE
Independent Director
COMPENSATION
$239K
AGE
56
TENURE
3.9 yrs

Dan Wolterman

TITLE
Director
COMPENSATION
$249K
AGE
61
TENURE
3.8 yrs

Don Rosenberg

TITLE
Lead Director
COMPENSATION
$241K
AGE
67
TENURE
1 yrs

Rob Friel

TITLE
Director
COMPENSATION
$229K
AGE
62
TENURE
3.3 yrs

Mike O'Halleran

TITLE
Director
COMPENSATION
$229K
AGE
68
TENURE
2.8 yrs

John DeFord

TITLE
Director
COMPENSATION
$240K
AGE
56
TENURE
1.3 yrs

Scott Huennekens

TITLE
Director
AGE
53
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess NuVasive's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. NuVasive has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company’s principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine to perform restorative and fusion procedures in a minimally-disruptive fashion. The company’s biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty and gel. Its IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, it offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and PRECICE, a limb lengthening system. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.

Details
Name: NuVasive, Inc.
NK8
Exchange: DB
Founded: 1997
$2,895,317,248
51,885,880
Website: http://www.nuvasive.com
Address: NuVasive, Inc.
7475 Lusk Boulevard,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS NUVA Common Stock Nasdaq Global Select US USD 13. May 2004
DB NK8 Common Stock Deutsche Boerse AG DE EUR 13. May 2004
BMV NUVA * Common Stock Bolsa Mexicana de Valores MX MXN 13. May 2004
Number of employees
Current staff
Staff numbers
2,600
NuVasive employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/22 20:38
End of day share price update: 2019/05/22 00:00
Last estimates confirmation: 2019/05/09
Last earnings filing: 2019/05/01
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.